5-(2-Methylpropyl)spiro[3,4,4a,5,7,7a-hexahydrofuro[3,4-b]pyran-2,2'-oxolane]

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡喃类
• 英文名称: 5-(2-Methylpropyl)spiro[3,4,4a,5,7,7a-hexahydrofuro[3,4-b]pyran-2,2'-oxolane]
• 英文别名: 5-(2-methylpropyl)spiro[3,4,4a,5,7,7a-hexahydrofuro[3,4-b]pyran-2,2'-oxolane]
• 化学式: C₁₄H₂₄O₃
• 分子量: 240.34
• InChiKey: RMPJZPSUTRSOIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof
  申请人：SUNSHINE LAKE PHARMA CO., LTD

  公开号：US20150079028A1

  公开（公告）日：2015-03-19

  Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

  提供了一种具有公式(I)的化合物，或其立体异构体、几何异构体、互变异构体、N-氧化物、水合物、溶剂化物、代谢物、药用盐或前药，可用于治疗HCV感染或HCV疾病。还提供了包含本处所述化合物的药物组合物，可用于治疗HCV感染或HCV疾病。
• Nitrogenous Heterocyclic Derivatives And Their Application In Drugs
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20150087639A1

  公开（公告）日：2015-03-26

  The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

  本发明涉及医学领域，提供了新颖的含氮杂环化合物，其制备方法及其作为药物的用途，特别是用于治疗和预防组织纤维化。还提供了包含这些含氮杂环化合物的药用组合物，以及这些组合物在治疗人类或动物组织纤维化方面的用途，特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。
• AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20160039838A1

  公开（公告）日：2016-02-11

  Provided herein are aminoquinazoline compounds, salts and uses thereof. The compounds have Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Also provided herein are pharmaceutical compositions containing the compounds disclosed herein, and uses of the compounds or the compositions for preventing, managing, treating or lessening the severity of a proliferative disorder in a patient and for modulating the protein tyrosine kinase activity.

  本文提供了氨基喹啉化合物、盐及其用途。该化合物具有式(I)、立体异构体、几何异构体、互变异构体、N-氧化物、水合物、溶剂化物、代谢产物、药学上可接受的盐或其前药。本文还提供了含有上述化合物的制药组合物，并使用该化合物或组合物预防、管理、治疗或减轻患者的增生性疾病严重程度，并调节蛋白酪氨酸激酶活性。
• SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
  申请人：Zhang Jiancun

  公开号：US20140147412A1

  公开（公告）日：2014-05-29

  Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions in the treatment of HCV infection or hepatitis C disease.
• SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20150232509A1

  公开（公告）日：2015-08-20

  A compound of formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.